Tag: ISA Pharmaceuticals
Company News: ISA Pharmaceuticals Appoints Ronald Loggers as Chief Executive Officer
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced that the Company has hired Ronald Loggers, the former Chairman of ISA´s Supervisory Board, as Chief Executive Officer.
Previously, Ronald Loggers, M.Sc., MBA, was Managing Director of Multifund B.V., a family-owned investment firm and one of ISA’s major investors. Until June 2013, he served as the Chairman of the Supervisory Board and subsequently assumed the role of Acting CEO of ISA Pharmaceuticals.
From 1998 to 2005, Ronald Loggers worked for private equity firm HAL Investments. During that period, he served on several boards such as the Supervisory Board of Schreiner Luchtvaart Groep B.V., and as Managing Director for the production and logistics facilities of optical retailer Pearle Benelux. From 1993 until 1998, he worked for McKinsey & Company. From 1991 to 1992, he was a manager at the quality control laboratories of Fokker Aircraft’s Ypenburg plant. Ronald Loggers holds an MBA from INSEAD and an M.Sc. in Chemical Engineering from Delft University of Technology.
Company News: New Clinical Data Demonstrate Strong Synergy between Cancer Vaccine ISA101 and Chemotherapy
– Data presented at the AACR Annual Meeting 2014
– Potential new treatment being developed for patients with late-stage cervical cancer
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, has announced new clinical data on its lead product candidate ISA101. ISA101 is a therapeutic cancer vaccine for the treatment of high-risk, HPV16-induced diseases, such as cervical cancer. The data were presented by principal investigator Prof. Sjoerd van der Burg, Ph.D., at this year’s American Association for Cancer Research (AACR) Annual Meeting in San Diego.
The data demonstrate strong synergy between ISA101 and chemotherapy, offering potential new treatment options for cervical cancer patients scheduled to receive standard chemotherapy with carboplatin / paclitaxel.
Prof. van der Burg and his group evaluated the immunological and clinical responses of patients with advanced cervical carcinoma in a Phase I combination trial. In this pilot trial, patients received ISA101 in combination with standard chemotherapy cycles (carboplatin / paclitaxel). Almost all patients showed a strong immune response to the ISA101 vaccine. Comprehensive immune monitoring confirmed the beneficial effect of myeloid suppressor cell depletion associated with a robust induction of HPV16-specific T-cell responses that were sustained throughout several cycles of chemotherapy.
The observation that depletion of myeloid suppressor cells by a carboplatin/paclitaxel chemotherapy regimen enhances the immune response to ISA101 is in line with prior observations that tumors promote immune tolerance starting early in the disease and that chemotherapy can restore immune competence in cancer patients.
Based on these results ISA has initiated a phase I/II study (CervISA) in October last year testing ISA101 in combination with carboplatin, paclitaxel and pegylated interferon alpha in women with advanced or recurrent cervical cancer.
The presentation titled “Synergistic effects of properly timed HPV16 SLP vaccination during standard carboplatin-paclitaxel chemotherapy in animals and patients with metastatic cervical carcinoma“ was given at the Minisymposium MS.IM02.01 “Immune-based Therapies: Responses, Biomarkers, and Mechanisms” on Monday, April 07, 2014, at 3:20 PM in Room 6CF at the San Diego Convention Center.
The abstract # 2938 is available at the AACR website www.aacr.org.
Company News: New Clinical Data on Cancer Vaccine ISA101 to Be Presented at the AACR Annual Meeting 2014
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, today announced that principal investigator Prof. Sjoerd van der Burg, Ph.D., will present new clinical data on ISA101 at this year’s American Association for Cancer Research (AACR) Annual Meeting. ISA101 is a therapeutic cancer vaccine for the treatment of high-risk, HPV16-induced diseases.
The presentation titled “Synergistic effects of properly timed HPV16 SLP vaccination during standard carboplatin-paclitaxel chemotherapy in animals and patients with metastatic cervical carcinoma“ will be given at the Minisymposium MS.IM02.01 “Immune-based Therapies: Responses, Biomarkers, and Mechanisms” on Monday, April 07, 2014, at 3:20 PM in Room 6CF at the San Diego Convention Center.
The abstract # 2938 is available at the AACR website www.aacr.org.
Company News: ISA Pharmaceuticals Strengthens Patent Protection for its Lead Product ISA101
– Granted EU patent provides market exclusivity until 2028 –
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, today announced it has been granted a European patent on its lead compound ISA101. The patent ensures market protection of ISA101’s active ingredient in Europe until 2028.
ISA101 is a therapeutic vaccine for the treatment of high-risk, HPV16-induced diseases. The vaccine consists of synthetic long peptides derived from the E6 and E7 oncogenic proteins of the HPV16 virus. This HPV strain is responsible, among others, for over 50% of human cervical cancers, more than 85% of HPV-positive head and neck cancers, and a variety of premalignant disorders.
The patent covers long peptides of the HPV-E6 protein, including a novel CD4+ epitope and provides exclusivity for the treatment of HPV-related diseases.
ISA101 is currently studied in the CervISA trial, a company-sponsored Phase I/II trial in cervical cancer and anal intra-epithelial neoplasia (AIN). Moreover, the vaccine has established clinical proof-of-concept by successfully completing a Phase II trial in vulvar intraepithelial neoplasia (VIN).